for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aptose Biosciences Inc

APTO.OQ

Latest Trade

2.05USD

Change

0.09(+4.59%)

Volume

23,403

Today's Range

1.97

 - 

2.11

52 Week Range

1.58

 - 

3.13

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.96
Open
1.98
Volume
23,403
3M AVG Volume
6.26
Today's High
2.11
Today's Low
1.97
52 Week High
3.13
52 Week Low
1.58
Shares Out (MIL)
55.45
Market Cap (MIL)
109.00
Forward P/E
-3.48
Dividend (Yield %)
--

Next Event

Q3 2019 Aptose Biosciences Inc Earnings Release

Latest Developments

More

Aptose Biosciences Reports Qtrly Net Loss Per Share Of $0.13

Aptose Announces Pricing Of Public Offering Of Common Shares

Aptose Announces Proposed Public Offering Of Common Shares

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aptose Biosciences Inc

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Industry

Biotechnology & Drugs

Contact Info

251 Consumers Rd Suite 1105

+1.647.4799828

https://aptose.com/

Executive Leadership

William Glenn Rice

Chairman of the Board, President, Chief Executive Officer

Gregory Kwok Lee Chow

Chief Financial Officer, Senior Vice President

Jotin Marango

Senior Vice President, Chief Business Officer

Carol Gail Ashe

Director

Caroline M. Loewy

Director

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.087

2017

-0.520

2018

-0.860

2019(E)

-0.562
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.22
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5.06
LT Debt To Equity (MRQ)
3.60
Return on Investment (TTM)
-90.67
Return on Equity (TTM)
-81.81

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up